EVAXION_DEEPBLUE_RGB.png
Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform
03 oct. 2024 08h00 HE | Evaxion Biotech
Improved precision of the AI-Immunology™ platform in predicting clinically relevant vaccine targets boosts the potential of its AI-derived vaccine candidates The improvement has been achieved through...
Logo.PNG
Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens®
03 oct. 2024 03h00 HE | Enara bio
New investors Pfizer Ventures and M Ventures co-led the financing, with participation from all existing investors including RA Capital, Samsara BioCapital and SV Health InvestorsEnara Bio’s EDAPT®...
Dr. Daniel Von Hoff
Distinguished Oncologist, Professor Daniel Von Hoff joins the Scientific/Clinical Advisory Board of EnGeneIC Cancer Therapeutics
01 oct. 2024 08h00 HE | EnGeneIC
EnGeneIC appoints Dr. Daniel Van Hoff to its Scientific Advisory Board to advise on clinical oncology programs, including upcoming PDAC trial.
plus_logo.png
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
01 oct. 2024 07h30 HE | Plus Therapeutics Inc.
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
GMILogo_Vertical-Gradient.png
Immune Checkpoint Inhibitors Market to hit USD 189.1 billion by 2032, says Global Market Insights Inc.
01 oct. 2024 05h30 HE | Global Market Insights Inc.
Selbyville, Delaware, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Immune Checkpoint Inhibitors Market size reached USD 47.4 billion in 2023 and is projected to register a CAGR of 16.7% from 2024 to 2032...
20231207IGIGlenmarkideantity™_SKHoriColourWBL.png
IGI Announces CRADA with National Cancer Institute to Test Proprietary Oral Cbl/b Inhibitor Treatment in Triple Negative Breast Cancer
30 sept. 2024 08h00 HE | Ichnos Glenmark Innovation
IGI Announces CRADA with National Cancer Institute to Test Proprietary Oral Cbl/b Inhibitor Treatment in Triple Negative Breast Cancer
AmMax-Logo_transparent.png
AmMax Bio to Present at the Oppenheimer Healthcare Private Company Showcase
27 sept. 2024 08h33 HE | AmMax Bio, Inc.
REDWOOD CITY, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- AmMax Bio, Inc., a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology, today announced that it...
JJ_Logo_SingleLine_Red_RGB.png
Novel combination of TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) suggest high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary disease
27 sept. 2024 08h21 HE | Janssen Cilag International NV
Data from the investigational Phase 1b RedirecTT-1 study demonstrate a safety profile consistent to talquetamab and teclistamab monotherapies1 BEERSE, BELGIUM, Sept. 27, 2024 (GLOBE NEWSWIRE) --...
AIMLogo.jpg
AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment
27 sept. 2024 08h00 HE | AIM ImmunoTech Inc.
OCALA, Fla., Sept. 27, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, Chief Executive Officer of AIM will...
Transparency Market Research
Orphan Drugs Market Size & Share to Surpass USD 424.0 billion by 2034, Rising a CAGR 6.9% | Analysis by Transparency Market Research, Inc.
26 sept. 2024 07h14 HE | Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The orphan drugs market (희귀의약품 시장) was worth US$ 195.0 billion in 2023. The market is...